FLGC vs. BIVI, HUGE, RNXT, VINC, LUMO, YMTX, GLTO, ONTX, SYBX, and MEIP
Should you be buying Flora Growth stock or one of its competitors? The main competitors of Flora Growth include BioVie (BIVI), FSD Pharma (HUGE), RenovoRx (RNXT), Vincerx Pharma (VINC), Lumos Pharma (LUMO), Yumanity Therapeutics (YMTX), Galecto (GLTO), Onconova Therapeutics (ONTX), Synlogic (SYBX), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical preparations" industry.
Flora Growth (NASDAQ:FLGC) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking.
Flora Growth has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 17.6% of Flora Growth shares are owned by company insiders. Comparatively, 4.8% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
BioVie has a net margin of 0.00% compared to Flora Growth's net margin of -75.33%. Flora Growth's return on equity of -60.26% beat BioVie's return on equity.
Flora Growth currently has a consensus price target of $7.00, indicating a potential upside of 323.99%. BioVie has a consensus price target of $8.00, indicating a potential upside of 1,588.48%. Given BioVie's higher probable upside, analysts clearly believe BioVie is more favorable than Flora Growth.
BioVie received 3 more outperform votes than Flora Growth when rated by MarketBeat users. Likewise, 64.00% of users gave BioVie an outperform vote while only 59.09% of users gave Flora Growth an outperform vote.
In the previous week, BioVie had 2 more articles in the media than Flora Growth. MarketBeat recorded 4 mentions for BioVie and 2 mentions for Flora Growth. Flora Growth's average media sentiment score of 0.72 beat BioVie's score of 0.34 indicating that Flora Growth is being referred to more favorably in the media.
BioVie has lower revenue, but higher earnings than Flora Growth. BioVie is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
Summary
Flora Growth beats BioVie on 9 of the 16 factors compared between the two stocks.
Get Flora Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FLGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Flora Growth Competitors List
Related Companies and Tools
